(GPC1)
. 8 Mounting evidence indicates that miR-149 may play a dual role in tumorigenesis. To be specific, miR-149 is generally recognized as a tumour suppressor with reduction in distinct cancers, [9] [10] [11] [12] while it is also reported that miR-149 could function as an oncogene. 8, 13, 14 In this review, we will summarize all the functions of miR-149 reported and its involving signalling pathways including numerous targets associated with cancer hallmarks, such as proliferation, resistance to apoptosis, epithelial-mesenchymal transition (EMT) and invasiveness in a variety of human cancers. Furthermore, the potential roles of miR-149 as a biomarker for diagnosis and prognosis of cancers and potential use of cancer treatment will be also discussed.
| B I OG ENE S IS AND S TRUC TURE OF MIR-149
The biogenesis of miR-149 is consistent with canonical miRNA biogenesis pathway ( Figure 1A ). 15 First, miR-149 is transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miR-149) in nucleus. The primary transcript is cleaved to a stem-loop precursor (pre-miR-149) containing 89-nt by the Drosha RNase III enzyme. The predicted secondary structure based on RNA structure online software (RNAfold web server) is shown in Figure 1B . Then, pre-miR-149 is exported to the cytoplasm with the help of RanGTP-dependent Exprotin5 and then further cleaved by the cytoplasmic Dicer RNase III to generate a miRNA/miRNA*duplex, which contains the mature miR-149 (also known miR-149-5p) and antisense miR-149* (also known miR-149-3p) products ( Figure 1C ). Based on numerous studies, miR-149-5p functions during various pathways through targeting various mRNAs in numerous tissues, while miR-149-3p may have specific functions in some specific cancer types and specific cases as well, such as melanoma under endoplasmic stress. 8 Interestingly, it was reported that miR-149-5p and miR-149-3p were highly co-expressed in brain and endothelial cellenriched tissues, such as lung and the well-accepted angiogenic tissue and participate in the modulation of endothelial cell proliferation in response to fibroblast growth factor (FGF) via fine tuning levels of GPC1 and FGFR1. 16 In fact, the majority of studies so far have been focused on miR-149-5p, and just few studies were focused on miR-149-3p. In this review, we will discuss both of the roles of miR-149-5p and miR-149-3p in human cancers.
| DYS REG UL ATI ON AND DUAL ROLE S OF MIR-149 IN H UMAN C AN CER S
Accumulating evidence has suggested that miRNAs may play critical roles in tumorigenesis, including proliferation, apoptosis, cell cycle, metastasis, etc. Interestingly, miR-149 has been shown to function as both a tumour suppressor and an onco-miR during the development of various types of cancers (Table 1) . For instance, compared with normal tissues, the level of miR-149-5p was found lower in non-smallcell lung cancer (NSCLC), hepatocellular carcinoma (HCC), gastric cancer (GC), colorectal cancer (CRC), breast cancer (BC), renal cell carcinoma (RCC), prostate cancer, glioma and upper tract urothelial carcinoma (UTUC) and have distinct functions, including proliferation inhibition, apoptosis induction, cell-cycle regulation and metastasis promotion, in various cancers separately. [9] [10] [11] [12] [17] [18] [19] [20] [21] [22] [23] On the contrar y, it has also been reported that miR-149-5p may be upregulated and functions as an oncogene in some certain tumours, including melanoma, nasopharyngeal carcinoma (NPC), glioma, T-cell acute lymphocytic leukaemia (T-cell ALL) and castrationresistant prostate cancer (CRPC). 8, 13, 14, 24, 25 For instance, an oncogenic role for miR-149-5p was seen in NPC in which significantly increased. 
| The upstream and downstream pathways involving in miR-149 dysregulation
There is an evolutionarily conserved cascade reaction of signal transduction concerning to the elementary cellular processes involving miR-149 (Table 1) . In this review, we made a brief summarization of the current knowledge associated with the regulatory network of miR-149 ( Figure 2 ). Accumulating evidence shows that miRNA dysregulation is contributed by both genetic and epigenetic alterations. 26 It was demonstrated that in melanoma, p53 directly upregulates miR-149-3p and then in turn targets GSK-3α, resulting in elevated expression of Mcl-1 and resistance to apoptosis. 8 XB130, also known as actin filament-associated protein 1-like 2 (AFAP1L2), is one of adaptor protein family. 27 Takeshita et al found that XB130
regulates expression of miR-149-5p negatively in human cancer cells, and the latter inhibits cell proliferation by directly targeting FOSL1
(also called Fra-1), which is a proto-oncogene. 28 In addition, it was verified that miR-149-5p along with miR-126 contributes to syndecan- 
TA B L E 1 (Continued)
Later in 2015, they studied further and provided evidence that miR-
149-5p together with some other miRNAs directly targets ErbB3 to block HRG-mediated viability of BC cells and hinders HRG-induced
MAPK and PI3K signalling and thus exerts tumour suppressive properties. 36 There was a study that depicts a relatively convenient and efficient method to gene targets of dysregulated miRNAs in human cancers. It shows that LOX, KCNMA1 and KCNAB1, which are oncogenes, are 3 predicted representative, direct targets of miR-149-5p. 39 Apart from of these, miR-149-3p along with 4 other miRNAs (miR-663a, miR-1908, miR-2861 and miR-3185) was upregulated in chordoma tissues compared with notochord tissues, and the 5 miRNAs were predicted to target genes encoding 7 elevated mRNAs (FGF2, JUND, DUSP4, MAP3K3, TGFB1, PRKACA and RAPGEF2), which are all involved in MAPK signalling pathway.
Thereby, it was speculated that the 5 miRNAs play vital roles in the regulation of MAPK pathways and have important effects in tumorigenesis of chordoma as a result. For SNP of miR-149, the latter mechanism is applicative. The association between miR-149 SNPs and various cancer risks has been explored in numerous previous studies. However, controversial experimental data were shown.
For miR-149 rs2292832 polymorphism, Li et al reported that rs2292832 is associated with a higher risk of digestive cancer risk, though the results were negative as regard to whole cancer risk. 43 Interestingly, another study showed that rs2292832 marginally contributes to gastrointestinal cancer susceptibility based on the pooled studies, especially for Asians. However, no significant associations were found when the analysis was stratified by cancer type, including CRC and GC. 44 It is a pity that in some studies no association was shown between rs2292832 with overall cancer risks. [45] [46] [47] [48] [49] [50] As regard to every concrete cancer type, the results in GC, squamous cell carcinomas of the non-oropharynx (SCCNOP), BC and papillary thyroid cancer (PTC) were consistent, while the results in other types of cancer are conflicting as well. Here, we mainly summarized the positive reports. It was shown that miR-149 rs2292832
CC genotype was associated with a higher risk of GC in the Greek population, the heterozygote TC genotype was associated with a decreased risk of gastric cancer, 51 and there were marginally significant associations for has-miR-149 rs2292832
with GC risk in male population. And interestingly, tea drinking was a protective factor in miR-149 rs2292832 for GC and could modify the associations of miR-149 polymorphisms with gastrointestinal cancer risk. 52 A recent study examined the effect 52 It was reported that rs2292832 was associated with significantly decreased risk of HCC, and the CC or CT genotype had a higher survival rate in patients at OKUDA stage II. 60 Another study showed that the miR-149 CC genotype has non-significant increased risk of HCC, particularly in HBV-infected patients. 61 In head and neck squamous cell carcinoma (HNSCC), Tu et al reported that the expression of miR-149 is decreased and that is correlated with an unfavourable survival of patients. 62 Moreover, the T/T genotype from the risk genotypes. 63 Moreover, it was found that the CC genotype of rs2292832 polymorphism was associated with risk of oral squamous cell carcinoma (OSCC) in South Indian population.
64
For miR-149 rs71428439 polymorphism, it was previously showed that rs71428439 resulted in a change in the structure of the miR-149 precursor and the G-allelic miR-149 precursor displayed a lower production of mature one. 42 Wu and colleagues found that patients with GG genotype express lower level of miR-149 thus higher AKT1 (a pre-validated 149 target in vitro) and have significantly higher risk of HCC in the Chinese Han population. 65 Another study by Wang et al showed that rs7142843 was significantly associated with increased ccRCC risk and may be a new biomarker for ccRCC susceptibility. CyclinD1 in U251 cells. 21 The results suggested that miR-149-5p targets p-AKT1, PCNA to inhibit glioma cell proliferation via blockade of the AKT1 signalling. The same conclusion was reached in Ghasemi's study in GBM. 38 Similarly, Zhang and colleagues validated that miR- These findings were similar to the conclusions of Wang et al on gastric cancer (GC) as well. 17 Also in laryngeal squamous cell carcinoma, miR-149-5p inhibits the proliferation and its low level is associated with stages, differentiation and metastasis. 67 The above studies hitherto show that miR-149-5p inhibits the proliferation of glioma, HCC and GC cells.
| MiR-149 and apoptosis
Apoptosis is known as programmed cell death process occurring in multicellular organisms, which is also an obstacle of cancer. As a con- Interestingly, just as above mentioned, Pan's study in GM cells in 2012 validated that miR-149-5p is lower in glioma and targets p-AKT1, PCNA to inhibit glioma cell proliferation and thus hinders glioma development. 21 Nevertheless this conclusion is contrary to Shen's, 24 which was performed in 2016. They demonstrated that the expression level of miR-149-5p is higher in glioma and inhibits cell apoptosis and promotes cell viability via caspase-2-p53-p21 pathway. More rigorous and convincing studies need to be performed and reach a convincing conclusion.
There is not only one apoptosis pathway correlated to miR-149-5p and miR-149-3p in distinct tumours, and the detailed mechanisms in specific tumour should be explored further.
| MiR-149 and cell cycle
It is generally recognized that cell cycle is a crucial process in which every component has distinct functions and the natural biochemical procedure impeded in some certain phase will af- 
| MiR-149 and metastasis (including EMT, migration and invasion)
Cancer is one of the most difficult issues and leads to death worldwide, mainly because of the development of metastasis at advanced stages of different cancers. Tumour metastasis contains a series of steps including separation, migration, invasion and so on.
Furthermore, EMT has vital effects on the process of cancer metastasis since its invasive and metastatic properties on cancer cells. 71 In view of advanced Forkhead box M1 (FOXM1) expression coincided with many cancers metastasis, 72 one study found that dual strands of pre-miR-149 inhibit migration and invasion through targeting FOXM1 in RCC. 73 Ke et al also demonstrated that miR-149-5p
inhibited EMT and metastasis of NSCLC cells by directly targeting FOXM1. 12 A similar mechanism in CRC was validated by Xu et al who demonstrated that miR-149-5p was obviously low in CRC tissues and that significantly repressed migration and invasion of CRC cells by targeting FOXM1. 74 Another study in CRC suggested that the downregulation of miR-149-5p contributes to the regulation of the SRPX2 (Sushi repeat containing protein, X-linked 2) transcript level, which may partly functions as a suppressor in migration or invasion through uPAR and FAK signalling. 34 Pan et al also found that miR-149-5p inhibits glioma migration and invasion through downregulation of one of its targets, MMP-2 expression via blockade of the AKT1 signalling. 21 Since that SRPX2 is known to exert migration enhancing function in GC cells. 75 Luo and colleagues found that miR-149-5p level is significantly lower, which was correlated with distant metastasis and TNM stage of HCC. 76 and Rap1b, which are downstream of integrin receptors in Bischoff's study. 10 As above discussed, the majority studies showed that miR-149-5p inhibits EMT and metastasis in most cancers. However, in NPC, the studies showed opposite conclusion. These studies indicated that miR-149-5p was upregulated in NPC cell lines and promoted the proliferation, mobility and invasion of NPC cells. Apart from these, miR-149-5p may be involved in the regulation of EMT via downregulating the E-cadherin level, while the inhibitor of miR-149-5p upregulated the E-cadherin level highly. 14, 78 These facts indicate that miR-149 may have different functions about tumour metastasis based on specific cancer type.
For miR-149-3p, a novel study demonstrated that its expression significantly hinders cell proliferation, migration and invasion in BC cells through one of its target S100A4 in Bladder cancer (BCa) cells. 79 Another study validated that the expression of miR-149-3p
can be used to evaluate the metastasis-free survival in uveral melanoma (UM) patients and shows a statistically significant correlation with liver metastasis. 80 Knowing well of the mechanisms by which miR-149 is associated with tumour metastasis will guide people to explore more effective directions of cancer treatment.
| MiR-149 and tumour microenvironment
Tumour development relies on the interactions between tumour and the surrounding microenvironment. Recent studies have demonstrated that cancer-associated fibroblasts (CAFs) play important roles in the crosstalk between tumour cells and their microenvironment to promote tumour growth, although they are not malignant themselves. 81 MiR-149 has also been found to be correlated with tumour microenvironment. Li and colleagues found that miR-149-5p is significantly downregulated due to PGE2-induced DNA methylation in CAFs from human GC tissues and is a critical factor for the transformation of NFs into CAFs in GC. 37 MiR-149-5p targets IL-6 and downregulates its expression to inhibit fibroblast activation and thus weakens EMT and stem-like properties of GC cells. 
| MiR-149 and tumour chemoresistance
Chemotherapy is one of the essential methods to resist cancers.
However, the resistance to chemotherapeutic agents is a clinical obstacle to the successful treatment of cancer, mainly because chemoresistant cancer cells have specific aberrant apoptotic response to drugs and acquire enhanced cell survival signals. MiR-149 has been
shown to be associated with chemoresistance as well. He et al found that miR-149-5p is downregulated due to hypermethylation of its 5′-UTR and is involved in chemoresistance in adriamycin-resistant human BC cells. 84 The underlying mechanism is that miR-149 targets 
| CLINI C AL APPLI C ATI ON S OF MIR-149 IN H UMAN C AN CER S

| MiR-149 as a biomarker for diagnosis and prognosis
It was demonstrated that miRNAs are present in the serum and plasma of humans and their levels in serum are stable. 86 Emerging evidence suggested that serum miRNAs can serve as potential biomarkers for the detection of various cancers 87 and specific miRNA profiles were capable of distinguishing malignant and non-malignant tissues, raising the feasibility of miRNAs in early detection of cancer, prognosis informing and treatment response monitoring. 88, 89 MiR-149 can be a biomarker as well. It was found that miR-149 was downregulated in PC and it combined with other 5 miRNAs (miR-96, miR-181b, miR-182, miR-205, miR-375) having an overall correct classification of 80% (AUV = 0.88), which can serve as one of powerful diagnostic markers for PC. 20 Berghmans et al performed a prospective study on patients with advanced NSCLC and treated with cisplatin and vinorelbine. They found that miR-149-5p and miR-375 could predict response and progressionfree survival in those patients. 90 Molina-Pinelo et al identified miRNA-dependent mRNA distinct profiles, aiming to discriminate SCC from adenocarcinoma histological subtypes of NSCLC.
Interestingly, it was found that miR-149-5p was over-expressed in SCC compared with adenocarcinoma and miR-149-5p's predicted target ABCC3 is validated and downregulated in SCC. 91 In HCC, miR-149 was found downregulated significantly and was associated with poor clinicopathologic features, such as larger tumour volume, capsular and vascular invasion, lymph node metastasis, high histological grade, TNM and BCLC grade. Also, low miR-149-5p was correlated with a low survival rate of HCC, as a result of being predictive factors for poor prognosis of HCC. 9, 76, 92 In BC, Perez-Rivas and colleagues identified 5 miRNAs, including miR-149-5p, downregulated in tumours from patients with early relapse, and found that the 5-miRNA signature represents highrisk early recurrence and a shorter relapse-free survival (RFS), as a result of having predictive value to distinct non-relapsing from early-relapsing patients and predict patients who have higher risk to develop metastasis early after primary surgery. 93 Moreover, there was one study showing that miR-149-5p expression is downregulated in progressing upper tract urothelial carcinoma (UTUC).
They identified the expression of miR-149-5p as independently associated with pathological tumour progression, tumour stage and cancer-specific survival and thus can be independent prognostic factors of cancer-specific survival. 23 In addition, similar to several other studies about the function of miR-149-5p in glioma, Xue et al validated that miR-149-5p was obviously lower, which is associated with Akt/mTOR signalling, and the level of miR-149-5p was significantly correlated with patients' survival duration. 94 Generally, miR-149-5p expression might be an eligible and independent indicator of diagnosis and prognosis of some cancers.
| MiR-149 as a therapeutic target for human cancers
Growing evidence has shown different effects of distinct drugs on different cancers. There have been several definite researches about association between miR-149 and chemotherapy agents.
One recent study 95 showed that the expression of miR-149 and miR-128 was reduced in glioblastoma and the expression of miR-149-5p is negatively correlated with grade, which is consistent with studies by Li. cell lines may represent promising targets for anti-cancer therapies. 97 As mentioned above, low miR-149-5p and positive PARP-2 (Poly(ADP-ribose) polymerase-1), which is also validated critical in tumour development, 98 are involved in pathogenesis of HCC and both miR-149-5p overexpression and PARP-2 inhibitor have anti-tumour effect, although targeting PARP-2 alone is a better strategy to treat with HCC in that PARP-2 inhibitor is a chemo/ radio sensor and can be used to strengthen chemotherapy and radiotherapy in HCC patients. Based on the study by Cao and colleagues, miR-149-3p was downregulated in GC but was upregulated by 18β-glycyrrhetinic acid (GRA), which is an anti-tumour agent by suppressing the tumorigenesis of GC. 99 The possible mechanism is that GRA upregulates miR-149-3p, resulting in downregulation of Wnt-1, and then together with amelioration of the inflammatory microenvironment through downregulation of COX-2 to inhibit the initiation and progression of GC. Moreover, a latest study performed by Si et al described that after dioscin treatment, miR-149-3p was upregulated and induced apoptosis and suppressed tumour growth in pancreatic cancer through inhibiting the Akt1 signalling pathway. 100 Based on the above clinical findings about the relationships between miR-149 and several specific agents towards some specific cancers, these findings revealed that it is very promising for miR-149 to be applied to the treatment of different tumours.
Actually, miRNA-based therapeutics have brought more and more concern recently, 101 including miRNA mimics and anti-miRs, aiming at tumour suppressors or onco-miRs, respectively. 102 However,
it remains obstacles about the use of miRNA-cased therapies, for example, the biological instability of the oligonucleotides and the poor cellular uptake. Fortunately, researchers have been making numerous attempts to solve the problems, mainly including different chemical modifications and delivery systems. 103 As to tissue or cell-specific targeting, several encapsulation methods, such as EnGeneIC Delivery Vehicle (EDV) nanocells (also called TargomiRs), 104 have been developed. What a pity is that there is no study about agents directly targeting miR-149 yet. Since miR-149-5p generally acts as a tumour suppressor in most cancers as above mentioned, the miR-149-5p mimics combining useful encapsulated and delivery methods may be a promising direction for treatment of those tumours.
| CON CLUS I ON AND FUTURE VIS I ON
Accumulating evidence hints that miRNAs are significant regulators of various cancers and could be utilized as novel biomarkers for cancer diagnosis, prognosis and treatment. In the past decades, miR-149 was verified to be aberrantly expressed in most cancers and widely studied in tissue or blood and has emerged as essential and critical components involved in tumorigenesis. In this review, we collected and introduced the already published literatures presenting miR-149 dysregulation in human malignancies and the mechanisms underlying miR-149-mediated carcinogenesis, such as proliferation, apoptosis, EMT and metastasis. To our best knowledge, this is the first review that systematically and mainly pays attention to the miR-149 roles in tumour development and progression. Although there are still some clinical roles of miR-149 in various cancers unravelled, there is no doubt that miR-149 is referred to the regulation of different pathways that are involved in development and progression of many type of cancers, and may act as a useful biomarker in diagnosis, prognosis and therapy prediction of human cancers. 
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